Effects of Berberine Hydrochloride and Bifidobacterium in Prediabetes Prevention and Treatment：an Open-label, Multicenter，Randomized, Prospective，Controlled Study
Trial Snapshot
- Phase
- Phase 2
- Status
- Withdrawn
- Sponsor
- Locations
- 4
- Primary Endpoint
- Change in 2-hour postprandial blood glucose between baseline to week 12
Study Overview
Brief Summary
The aim of this study is to assess the beneficial effects of Bifidobacterium and Berberine Hydrochloride on lowering glucose and delaying progress to diabetes in patients with prediabetes and to detect the potential mechanism.
Detailed Description
Gut microbiota may play an important role in patients with prediabetes. Berberine, which is usually used as an antibiotic drug, has been reported a potential glucose-lowering effect in vitro and in vivo studies. Bifidobacterium, as a familiar probiotics, can modulate gut microbiota and improve glucose and lipid metabolism in animal experiments. Therefore, the aim of this study is to assess the beneficial effects of Bifidobacterium and Berberine Hydrochloride on lowering glucose and delaying progress to diabetes in patients with prediabetes and to detect the potential mechanism.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Prevention
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to 70 Years (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Informed consent obtained before any trial-related activities
- •Male or female between 18 and 70 years of age
- •19≤Body mass index(BMI)≤30kg/m2
- •No participate in any clinical trial at least 3 months
- •Fasting blood glucose(FBG)<7.0mmol/L and 2-hour postprandial blood glucose(2hPBG)<11.1mmol/L
- •Females in child-bearing period should be given birth control
- •No severe disease about heart, lung and kidney
- •Ability and willingness to adhere to the protocol including performance of self-monitored blood glucose (SMBG) profiles according to the protocol;
- •Subject is likely to comply with the Investigators instruction.
Exclusion Criteria
- •Type 2 diabetes mellitus or type 1 diabetes mellitus
- •Females of childbearing potential who are pregnant，breastfeeding or intend to become pregnant or are not using adequate contraceptive methods
- •Impaired liver function, defined as Aspartate aminotransferase(AST) or Alanine transaminase(ALT)> 2 times upper limit of normal (central laboratory)
- •Impaired renal function, defined as serum-creatinine≥133μmol/L
- •Uncontrolled treated/untreated severe hypertension (systolic blood pressure≥160mmHg and /or diastolic blood pressure≥95mmHg)
- •Chronic gastrointestinal diseases
- •Cancer and medical history of cancer (except basal cell skin cancer or squamous cell skin cancer)
- •Any clinically significant disease or disorder, which in the Investigator's opinion could interfere with the results of the trial
- •Mental incapacity, psychiatric disorder, unwillingness or language barriers precluding adequate understanding or co-operation, including subjects not able to read and write
- •Previous participation in this trial. Participation is defined as randomized. Re-screening of screening failures is allowed only once within the limits of the recruitment period
- •Known or suspected hypersensitivity to trial products or related products
- •Known or suspected abuse of alcohol, narcotics or illicit drugs.
Arms & Interventions
Bifidobacterium viable pharmaceutics
Bifidobacterium viable pharmaceutics, 2 Capsules, 2/day, 12 weeks
Intervention: Bifidobacterium viable pharmaceutics (Drug)
Berberine Hydrochloride
Berberine Hydrochloride, 0.5g, 2/day, 12 weeks
Intervention: Berberine Hydrochloride (Drug)
Outcomes
Primary Outcomes
Change in 2-hour postprandial blood glucose between baseline to week 12
Time Frame: Baseline and Week 12
2-hour postprandial blood glucose are measured at baseline and week 12 during a 2 hour-meal test.
Secondary Outcomes
- Gut microbiome composition(Baseline and week 12)
- Adverse effects(From baseline to week 12)